X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206554
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204230
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211001
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214739
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214576
https://www.prnewswire.com/news-releases/apotex-corp-launches-bendamustine-hydrochloride-injection-in-the-united-states-301808721.html
https://www.globenewswire.com/news-release/2023/04/05/2641508/0/en/Eagle-Pharmaceuticals-Reaches-Settlement-Agreement-with-Dr-Reddy-s-Laboratories-Inc-and-Dr-Reddy-s-Laboratories-Ltd-Related-to-BENDEKA-bendamustine-hydrochloride.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214739
https://www.globenewswire.com//news-release/2022/12/12/2571679/0/en/Eagle-Pharmaceuticals-Reaches-Settlement-Agreement-with-Accord-Healthcare-Inc-Related-to-BENDEKA-bendamustine-hydrochloride.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205376
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205574
https://recalls-rappels.canada.ca/en/alert-recall/nat-bendamustine-discoloration
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205447
https://www.fiercepharma.com/pharma/beigene-keeps-momentum-going-brukinsa-winning-nice-recommendation-wm
https://www.globenewswire.com/news-release/2022/04/19/2424213/0/en/Eagle-Pharmaceuticals-Reaches-Settlement-Agreement-with-Hospira-Related-to-BENDEKA-bendamustine-hydrochloride-until-January-17-2028.html
https://www.prnewswire.com/news-releases/oncopeptides-presents-new-clinical-and-preclinical-melflufen-data-at-the-upcoming-european-hematology-association-meeting-301289913.html
https://www.businesswire.com/news/home/20210430005136/en/Eagle-Pharmaceuticals-Announces-TREAKISYM-bendamustine-Ready-to-Dilute-%E2%80%9CRTD%E2%80%9D-Formulation-in-Combination-with-Rituximab-for-Treatment-of-Relapsed-or-Refractory-Diffuse-Large-B-cell-Lymphoma-Receives-PMDA-Approval-in-Japan
https://www.gov.uk/drug-safety-update/bendamustine-levact-increased-risk-of-non-melanoma-skin-cancer-and-progressive-multifocal-encephalopathy-pml
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204230
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205574
https://www.thehindubusinessline.com/companies/teva-moves-us-court-against-aurobindo-pharma-on-cancer-drug-bendeka/article31582085.ece
http://www.pharmafile.com/news/547553/teva-s-cancer-drug-bendeka-protected-generics-until-2031-judge-rules
https://www.bloomberg.com/news/articles/2020-04-27/teva-wins-ruling-on-patents-for-bendeka-cancer-drug
https://www.biospace.com/article/releases/court-issues-favorable-patent-litigation-decision-for-eagle-pharmaceuticals-inc-and-teva-pharmaceutical-industries-ltd-for-bendeka-bendamustine-hydrochloride-injection-/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211001
https://www.biospace.com/article/adc-therapeutics-adds-103-million-to-series-e-to-total-303-million/
https://www.biospace.com/article/astrazeneca-has-dazzled-in-recent-cancer-trials-but-faces-stiff-competition/
https://www.fiercepharma.com/pharma/astrazeneca-s-calquence-sets-imbruvica-its-sights-promising-solo-cll-data
https://www.fiercepharma.com/pharma/roche-touts-phase-2-gazyva-data-lupus-nephritis-same-day-as-new-approval
https://www.fiercepharma.com/pharma/roche-snags-fda-approval-for-polivy-combo-certain-dlbcl-patients
https://www.fiercepharma.com/pharma/az-s-calquence-chases-imbruvica-new-phase-3-leukemia-data
https://www.fiercepharma.com/pharma/trapped-by-orphan-drug-program-fda-blocks-generic-cancer-drug-for-3-extra-years
https://www.raps.org/news-and-articles/news-articles/2019/2/additional-exclusivity-for-a-cancer-treatment-coul
https://endpts.com/additional-exclusivity-for-a-cancer-treatment-could-cost-the-public-3-billion-analyst-says/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204771
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204104
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205447
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205574
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205757
https://globenewswire.com/news-release/2018/11/01/1640780/0/en/Roche-announces-EU-approval-of-Venclyxto-plus-MabThera-for-people-with-previously-treated-chronic-lymphocytic-leukaemia.html
https://www.pharmacompass.com/pdf/news/bendamustine-hydrochloride-injection-eagle-pharmaceuticals-vs-slayback-pharma-1537861606.pdf
Market Place
Share 
